Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
Compounds of formula (I): wherein: R 1 represents hydrogen, halogen, alkyl, polyhaloalkyl, cyano, nitro, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl, R 2 represents hydrogen, alkyl, an optionally substituted aryl, optionally substituted heteroaryl, or R 20 —C(X)— wherein: R 20 represents alkyl, alkoxy, amino, alkylamino, dialkylamino, optionally substituted aryl or optionally substituted heteroaryl, X represents oxygen, sulphur, or NR 21 wherein R 21 represents hydrogen or alkyl, R 3 represents hydrogen atom or alkyl, n represents integer from 1 to 6 inclusive, the representation its enantiomers, diastereoisomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as AMPK activators.
1. A compound of formula (I):
wherein:
R 1 represents hydrogen, halogen, alkyl, polyhaloalkyl, cyano, nitro, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl,
R 2 represents hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, or R 20 —C(X)— wherein:
R 20 represents alkyl, alkoxy, amino, alkylamino, dialkylamino, optionally substituted aryl or optionally substituted heteroaryl,
X represents oxygen, sulphur, or NR 21 wherein R 21 represents hydrogen or alkyl,
R 3 represents hydrogen or alkyl,
n represents an integer from 1 to 6 inclusive,
the representation
its enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base,
the term “alkyl” denotes linear or branched hydrocarbon chain having from 1 to 6 carbon atoms,
the term “alkoxy” denotes an alkyl-oxy in which the alkyl chain, which is linear or branched, has from 1 to 6 carbon atoms,
the term “aryl” denotes phenyl or biphenyl,
the term “polyhaloalkyl” denotes a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms,
the term “heteroaryl” denotes a group having from 5 to 11 ring members which is monocyclic or bicyclic, in which at least one of the rings is aromatic, and which contains in the monocyclic ring system or in the bicyclic ring system 1, 2 or 3 hetero atoms selected from nitrogen, oxygen and sulphur, and
the expression “optionally substituted” associated with the expressions aryl and heteroaryl means that the groups in question may be substituted by one or two identical or different substituents selected from halogen, alkyl, alkoxy, polyhaloalkyl, hydroxy, cyano, nitro, amino (optionally substituted by one or two alkyl groups) and —C(O)R d wherein R d represents a group selected from hydroxy, alkoxy and amino, and wherein the heteroaryl may also be substituted by an oxo moiety on the non-aromatic moiety of the heteroaryl.
2. A compound of claim 1 , wherein the representation
3. A compound of claim 1 , wherein R 1 represents hydrogen.
4. A compound of claim 1 , wherein R 2 represents hydrogen.
5. A compound of claim 1 , wherein R 2 represents a group R 20 —C(O)—.
6. A compound of claim 1 , wherein R 3 represents hydrogen.
7. A compound of claim 1 , wherein R 20 represents alkoxy.
8. A compound of claim 1 , wherein n represents an integer from 4 to 6 inclusive.
9. A compound of claim 1 , wherein
R 1 represents hydrogen, R 2 represents hydrogen or a group R 20 —C(O)—, wherein R 20 represents alkoxy, and n is 4 or 5.
10. A compound of claim 1 , which is 3-cycloheptyl-3H-imidazo[4,5]pyridine-2-amine.
11. A compound of claim 1 , which is 3-cyclooctyl-3H-imidazo[4,5]pyridine-2-amine.
12. A pharmaceutical composition useful as an AMPK activator, comprising as active principle and effective amount of a compound as claimed in claim 1 , together with one or more inert, non-toxic, pharmaceutically acceptable excipients or vehicles.
13. A method for treating a living animal body afflicted with a condition selected from non-insulin-dependent, type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and their cardiovascular complications, comprising the step of administering to the living animal body an amount of a compound of claim 1 , which is effective for alleviation of the condition.
14. A method for treating a living animal body afflicted with a condition selected from type I and II diabetes and their cardiovascular complications, comprising the step of administering to the living animal body an amount of a compound of claim 1 , which is effective for alleviation of the condition.
15. A method for treating a living animal body afflicted with a condition selected from type I and II diabetes, comprising the step of administering to the living animal body an amount of a compound of claim 1 , which is effective for alleviation of the condition.
16. A method for treating a human afflicted with a condition selected from non-insulin-dependent, type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and their cardiovascular complications, comprising the step of administering to the human an amount of a compound of claim 1 , which is effective for alleviation of the condition.
17. A method for treating a human afflicted with a condition selected from type I and II diabetes and their cardiovascular complications, comprising the step of administering to the human an amount of a compound of claim 1 , which is effective for alleviation of the condition.
18. A method for treating a human afflicted with a condition selected from type I and II diabetes, comprising the step of administering to the human an amount of a compound of claim 1 , which is effective for alleviation of the condition.